Search research articles
Contact Us
Filters
Showing results (191-200 of 206) with videos related to
Page
of 21
Sort By:
International Journal of Cancer
|
March 12, 2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3
Ryuma Tokunaga, Shu Cao, Madiha Naseem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2023
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, et al.
International Journal of Cancer
|
July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)
Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
Arndt Stahler, Beeke Hoppe, Il-Kang Na, et al.
Cancers
|
July 27, 2022
Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL
Jörg Kumbrink, Lisa Bohlmann, Soulafa Mamlouk, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
British Journal of Cancer
|
May 31, 2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2025
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study
Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2025
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
Francesca Battaglin, Bert H O'Neil, Sebastian Stintzing, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 206) with videos related to
Sort By:
Page
of 21
International Journal of Cancer
|
March 12, 2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3
Ryuma Tokunaga, Shu Cao, Madiha Naseem, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2023
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, et al.
International Journal of Cancer
|
July 26, 2021
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)
Arndt Stahler, Volker Heinemann, Julian Walter Holch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2023
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)
Arndt Stahler, Beeke Hoppe, Il-Kang Na, et al.
Cancers
|
July 27, 2022
Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL
Jörg Kumbrink, Lisa Bohlmann, Soulafa Mamlouk, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
British Journal of Cancer
|
May 31, 2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2025
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study
Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 13, 2025
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)
Francesca Battaglin, Bert H O'Neil, Sebastian Stintzing, et al.
Page
of 21